KPIs & Operating Metrics(New)
Growth Metrics

Johnson & Johnson (JNJ) Other Non-Current Liabilities (2009 - 2026)

Johnson & Johnson recorded quarterly Other Non-Current Liabilities of $486.0 million in Q1 2026, little changed quarter-over-quarter from $486.0 million in Q4 2025, and down 60.52% year-over-year from $1.2 billion in Q1 2025.

Johnson & Johnson's Other Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $486.0 million for Q1 2026.

  • In Q1 2026, Other Non-Current Liabilities fell 60.52% year-over-year to $486.0 million; the TTM figure through Mar 2026 stood at $486.0 million (down 60.52% YoY), while the FY2025 annual figure was $486.0 million, down 60.07% from the prior year.
  • Other Non-Current Liabilities came in at $486.0 million for Q1 2026 at Johnson & Johnson, roughly flat from $486.0 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $10.3 billion in Q2 2025 to a low of $486.0 million in Q2 2022.
  • A 5-year average of $1.9 billion and a median of $1.1 billion in 2023 frame the typical range for Other Non-Current Liabilities.
  • Across the five-year window, Other Non-Current Liabilities surged 722.36% in 2025 and plunged 60.52% in 2026, its largest moves.
  • Johnson & Johnson's Other Non-Current Liabilities stood at $525.0 million in 2022, then soared by 108.0% to $1.1 billion in 2023, then advanced by 11.45% to $1.2 billion in 2024, then tumbled by 60.07% to $486.0 million in 2025, then changed by 0.0% to $486.0 million in 2026.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $486.0 million, $486.0 million, and $9.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 29, 2026 486.00 Mn
Dec 28, 2025 486.00 Mn
Sep 28, 2025 9.93 Bn
Jun 29, 2025 10.26 Bn
Mar 30, 2025 1.23 Bn
Dec 29, 2024 1.22 Bn
Sep 29, 2024 1.22 Bn
Jun 30, 2024 1.25 Bn
Mar 31, 2024 1.11 Bn
Dec 31, 2023 1.09 Bn
Oct 1, 2023 1.18 Bn
Jul 2, 2023 1.14 Bn
Apr 2, 2023 1.14 Bn
Jan 1, 2023 1.12 Bn
Oct 2, 2022 525.00 Mn
Jul 3, 2022 536.00 Mn
Apr 3, 2022 486.00 Mn
Jan 2, 2022 533.00 Mn
Oct 3, 2021 613.00 Mn
Jul 4, 2021 593.00 Mn
Apr 4, 2021 600.00 Mn
Jan 3, 2021 633.00 Mn
Sep 27, 2020 636.00 Mn
Jun 28, 2020 796.00 Mn
Mar 29, 2020 10.94 Bn
Dec 29, 2019 1.72 Bn
Sep 29, 2019 1.64 Bn
Jun 30, 2019 1.56 Bn
Mar 31, 2019 452.00 Mn
Dec 30, 2018 397.00 Mn
Sep 30, 2018 8.54 Bn
Jul 1, 2018 9.28 Bn
Apr 1, 2018 8.88 Bn
Dec 31, 2017 600.00 Mn
Oct 1, 2017 9.10 Bn
Jul 2, 2017 10.12 Bn
Apr 2, 2017 9.53 Bn
Jan 1, 2017 9.54 Bn
Oct 2, 2016 9.41 Bn
Jul 3, 2016 10.06 Bn
Apr 3, 2016 9.75 Bn
Jan 3, 2016 10.24 Bn
Sep 27, 2015 9.30 Bn
Jun 28, 2015 8.97 Bn
Mar 29, 2015 8.60 Bn
Dec 28, 2014 8.03 Bn
Sep 28, 2014 7.76 Bn
Jun 29, 2014 7.37 Bn
Mar 30, 2014 7.27 Bn
Dec 29, 2013 7.85 Bn
Sep 29, 2013 8.90 Bn
Jun 30, 2013 8.57 Bn
Mar 31, 2013 8.20 Bn
Dec 30, 2012 8.55 Bn
Sep 30, 2012 9.21 Bn
Jul 1, 2012 9.49 Bn
Apr 1, 2012 10.54 Bn
Jan 1, 2012 10.63 Bn
Oct 2, 2011 7.47 Bn
Jul 3, 2011 7.23 Bn
Apr 3, 2011 7.00 Bn
Jan 2, 2011 6.57 Bn
Oct 3, 2010 6.23 Bn
Jul 4, 2010 6.36 Bn
Apr 4, 2010 6.04 Bn
Jan 3, 2010 5.95 Bn
Sep 27, 2009 5.05 Bn
Jun 28, 2009 4.28 Bn